MOONLAKE IMMUNO (MLTX)
(Delayed Data from NSDQ)
$46.65 USD
+1.68 (3.74%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $46.67 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MLTX 46.65 +1.68(3.74%)
Will MLTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MLTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLTX
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
MLTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%
Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates
MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for MLTX
MoonLake Immunotherapeutics initiated with bullish view at Oppenheimer, here's why
MoonLake Immunotherapeutics’ Strong Buy Rating Backed by Promising Sonelokimab (SLK) Clinical and Regulatory Advancements
Buy Rating Affirmed: MoonLake Immunotherapeutics’s Sonelokimab Poised for Multiple Indication Success
Needham Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
Analysts Are Bullish on Top Healthcare Stocks: AC Immune SA (ACIU), MoonLake Immunotherapeutics (MLTX)